TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from PolyPid ( (PYPD) ).
PolyPid Ltd. announced on September 16, 2025, the successful completion of a Good Manufacturing Practice (GMP) inspection by the Israeli Ministry of Health, marking its fourth consecutive successful inspection. This milestone confirms PolyPid’s readiness for commercial manufacturing of D-PLEX100, a key step towards its global commercialization following the positive Phase 3 SHIELD II trial results. The inspection aligns with European regulatory standards, reinforcing the company’s path to market entry in both the U.S. and European markets.
The most recent analyst rating on (PYPD) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on PolyPid stock, see the PYPD Stock Forecast page.
Spark’s Take on PYPD Stock
According to Spark, TipRanks’ AI Analyst, PYPD is a Neutral.
PolyPid’s score reflects significant financial challenges, including consistent losses and negative equity. While the company’s clinical advancements and financing efforts are promising, they are not sufficient to offset the financial risks. The stock exhibits neutral technical indicators and an unattractive valuation, limiting its appeal to investors.
To see Spark’s full report on PYPD stock, click here.
More about PolyPid
PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through locally administered, controlled, prolonged-release therapeutics. The company’s proprietary PLEX technology enables precise drug delivery over extended periods. PolyPid’s lead product candidate, D-PLEX100, is aimed at preventing surgical site infections, with a New Drug Application submission expected in early 2026. The company also has a pipeline in oncology, obesity, and diabetes.
Average Trading Volume: 115,157
Technical Sentiment Signal: Sell
Current Market Cap: $34.55M
For a thorough assessment of PYPD stock, go to TipRanks’ Stock Analysis page.